Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

SciSparc Ltd. Ordinary Shares · SPRC

SPRCNASDAQCommon stockCurrentCIK 1611746Updated Nov 21, 2026

Company: SciSparc Ltd. →

Name history
SciSparc Ltd./ADR · through Aug 27, 2021Therapix Biosciences Ltd. · through Jan 28, 2021

SPRC price & chart

Provider market data

Loading TradingView…

NASDAQ:SPRC on TradingView ↗

TradingView · Data may be delayed

About the company

SciSparc Ltd. is undergoing a strategic transformation toward Agentic AI-powered technologies, with a focus on applications in cybersecurity and finance. Building on its decision to target the Agentic AI market and the establishment of a Scientific Advisory Board for AI and cybersecurity, the Company is evaluating technologies, companies and business opportunities across the Agentic AI ecosystem. Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives.

6-K · 2026-11-16 · 0001213900-26-120588

Company description from the cited filing.

Financials

FY 2024 · USD
Revenue1,306,000USD · FY 2024
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

Net income-6,284,000USD · FY 2024
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

Assets—USD · FY 2024
Cash— · FY 2024
Operating income-7,316,000USD · FY 2024
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

Diluted EPS26.94USD per share · FY 2024
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ2 2018FY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Profit or LossUSD-1,214,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

-7,472,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-5,883,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

-2,592,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

-5,789,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

Additional Financial Items
AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD-50,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

12,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

55,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

3,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

170,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD-101,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

25,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-397,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

—353,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

AdjustmentsForSharebasedPaymentsUSD138,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

569,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

196,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

—43,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

GeneralAndAdministrativeExpenseUSD1,000,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

4,526,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

5,031,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

6,509,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

3,778,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

InterestPaidClassifiedAsFinancingActivitiesUSD—8,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

7,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

——
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD—54,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

47,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

——
ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD———9,005,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

7,699,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

ProceedsFromIssuingSharesUSD—6,255,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

———
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD———4,861,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ2 2022Q2 2018FY 2024FY 2023FY 2022FY 2021
Cost of Goods and Services Sold———
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

—
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

—
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
Selling, General and Administrative ExpenseUSD———5,031,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

6,509,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

3,778,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

Total RevenueUSD——1,306,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

2,879,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

1,347,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
Additional Financial Items
ApplicableTaxRatenumber———0.23
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

0.23
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

0.23
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

BasicEarningsLossPerShareUSD per share——26.94
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

14.43
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

—2.83
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

DilutedEarningsLossPerShareUSD per share——26.94
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

14.43
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

——
EmployeeBenefitsExpenseUSD——106,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

105,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

115,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

98,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

FinanceCostsUSD—1,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

353,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

1,055,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

2,014,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

21,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

FinanceIncomeUSD—437,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

612,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

2,219,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

7,832,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
GeneralAndAdministrativeExpenseUSD—1,000,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

4,526,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

5,031,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

6,509,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

3,778,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

GrossProfitUSD10,210,000
Source

6-K · 2025-11-18 · 0001213900-25-112079

As of 2022-06-01

—506,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

2,196,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

1,025,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD——1,344,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

———
IncomeTaxExpenseContinuingOperationsUSD——-14,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

22,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

14,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
OtherIncomeUSD——1,270,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

———
OtherOperatingIncomeExpenseUSD————-109,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
ProfitLossAttributableToNoncontrollingInterestsUSD——-1,188,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-761,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

——
ProfitLossAttributableToOwnersOfParentUSD——-6,284,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-5,122,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

2,592,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

5,789,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

ProfitLossBeforeTaxUSD——-7,486,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-5,861,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

-2,578,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—
ProfitLossFromOperatingActivitiesUSD—-1,650,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

-7,316,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-6,815,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

-8,287,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

-5,768,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

ResearchAndDevelopmentExpenseUSD—650,000
Source

6-K · 2018-11-28 · 0001213900-18-016621

2018-04-01 to 2018-06-30

1,707,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

1,641,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

2,803,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

1,990,000
Source

20-F · 2022-04-28 · 0001213900-22-022294

2021-01-01 to 2021-12-31

ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD——-429,000
Source

6-K · 2025-07-22 · 0001213900-25-066626

2024-01-01 to 2024-12-31

-210,000
Source

20-F/A · 2024-05-02 · 0001213900-24-038779

2023-01-01 to 2023-12-31

-109,000
Source

20-F · 2023-05-01 · 0001213900-23-034606

2022-01-01 to 2022-12-31

—

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-299929

F-3 · 2026-11-09 · 0001213900-26-117517

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-293533

F-3/A · 2026-08-19 · 0001213900-26-091651

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-293167

F-3 · 2026-02-03 · 0001213900-26-011504

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ea031240801ex99-1.htm · 6-K · 2026-11-16

Exhibit 99.1 SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB Appointment of the former Head of Israel’s National Security Council and Former Acting National Security Advisor to Prime Minister Benjamin Netanyahu marks another step in laying the scientific and strategic foundation for SciSparc’s planned entry into the Agentic AI sector TEL AVIV, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: …

6-K · 2026-11-16 · 0001213900-26-120588

Read attachment ↗
ea031140201ex4-1.htm · 6-K/A · 2026-11-09

Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…

6-K/A · 2026-11-09 · 0001213900-26-117211

Read attachment ↗
ea031140201ex4-2.htm · 6-K/A · 2026-11-09

Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED B…

6-K/A · 2026-11-09 · 0001213900-26-117211

Read attachment ↗
ea031077601ex4-1.htm · 6-K · 2026-11-03

Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…

6-K · 2026-11-03 · 0001213900-26-115602

Read attachment ↗
ea031077601ex4-2.htm · 6-K · 2026-11-03

Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED B…

6-K · 2026-11-03 · 0001213900-26-115602

Read attachment ↗
ea030941001ex99-1.htm · 6-K · 2026-10-23

Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food …

6-K · 2026-10-23 · 0001213900-26-111852

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.